Europlasma is a French company listed on Euronext Growth, specializing in waste treatment technologies using plasma torches. Its stock price currently hovers around one cent euro, following years of massive dilution linked to convertible bond financing. Understanding this dilution mechanism is a prerequisite before any reflection on Europlasma’s stock.
Convertible Bond Financing and Europlasma’s Capital Dilution
Europlasma’s financing model is based on the issuance of convertible bonds. The principle: the company issues bonds to a fund, which then converts them into new shares at a discounted price compared to the stock market price. Each conversion creates new shares, increasing the total number of shares outstanding.
Read also : Spotlight on the Inspiring Journeys of French Media Personalities
For existing shareholders, each conversion mechanically reduces their stake in the capital. The stock price experiences constant selling pressure, as the converting fund generally sells its shares on the market shortly after conversion.
A press release published by Europlasma on May 12, 2026, confirms the establishment of new bond financing and announces the postponement of the publication of accounts. This sequence, yet another recourse to convertible debt combined with an accounting delay, illustrates the cycle in which the company has been operating for several years. To delve deeper into the future of Europlasma on A Vos Finances, the details of these financial mechanisms are analyzed there.
Related reading : Discover the Fastest 125cc Motorcycle on the Market
The Role of the ABO Fund in Europlasma’s Stock Journey
The financier Alpha Blue Ocean (ABO), founded by Pierre Vannineuse and based in London, has played a central role in financing Europlasma. ABO has provided capital through convertible bond arrangements, becoming the company’s main liquidity provider.
This link has been documented beyond financial press. An investigative commission of the National Assembly on hedge funds examined ABO’s role in the dissemination of this financing. The arrangement operates according to a recurring pattern:
- ABO subscribes to convertible bonds under favorable conditions, with a conversion price lower than the market price.
- The conversion generates an influx of new shares that weighs on the stock price, making each new tranche even more dilutive.
- The historical shareholder sees their participation decrease with each operation, with no real possibility of opposing it.
dilution is not a side effect of financing, it is the financing itself. The fund derives its remuneration from the gap between the conversion price and the resale price on the market.
Ceasing Defense Activities: One Growth Driver Less
Europlasma has long highlighted two operational pillars: the treatment of hazardous waste (notably asbestos) using plasma torches, and the dismantling of munitions for the defense sector. This second axis fueled part of the discourse on the company’s potential.
In early 2025, Europlasma officially announced the cessation of its defense activities. This refocusing removes one of the most frequently cited growth drivers in analyses favorable to the stock. The company is now concentrating its efforts on the energy recovery of waste, a promising market on paper but where Europlasma struggles to demonstrate stable operational profitability.
This strategic choice raises a concrete question: will the refocusing on depollution be enough to generate recurring revenues capable of covering financing needs without systematically resorting to new bond issuances?
Continuity of Operations and Accounting Signals to Watch
The postponement of the publication of accounts announced in May 2026 is a signal to take seriously. In accounting, the mention of doubt about continuity of operations in an audit report means that the auditors believe that the company may not be able to continue its activities in the following twelve months.
Specialized stock forums, particularly on Boursorama, have recurrently raised this issue. A message from May 2, 2026, directly questions the compromised continuity of operations for Europlasma.
For a retail investor, several elements deserve verification before making any decision:
- The presence or absence of a mention of continuity of operations in the latest available audit report.
- The evolution of the number of shares outstanding from one quarter to another, a direct indicator of the dilution rate.
- The amount of convertible bond debts remaining to be converted, which foreshadows future dilution.
- The company’s ability to publish its accounts within regulatory deadlines.
Europlasma Stock on the Market: Real Risk Profile for the Investor
Europlasma’s stock regularly attracts retail investors drawn by a very low unit price, hoping for a spectacular rebound. This reasoning is based on a frequent confusion: a low price does not mean a low valuation. Market capitalization depends on the product of the price by the number of shares, and this number has been multiplied by successive conversions.
The stock presents a risk profile characteristic of micro-capitalizations subject to structural dilution. Volatility is extreme, volumes can be very low, and liquidity can disappear abruptly. The information asymmetry between the financing fund (which knows the exact conversion conditions) and the individual shareholder remains a disadvantageous factor for the latter.
Europlasma’s journey illustrates a pattern found in other French micro-capitalizations financed by convertible bonds. The stock may occasionally rebound on an announcement or rumor, but the underlying trend remains dictated by the dilution mechanism as long as the company fails to self-finance through its operational activities. Betting on Europlasma today amounts to wagering on an operational turnaround in a context where the accounting fundamentals remain fragile.